Literature DB >> 27318125

A combination of two truncating mutations in USH2A causes more severe and progressive hearing impairment in Usher syndrome type IIa.

Bas P Hartel1, Maria Löfgren2, Patrick L M Huygen3, Iris Guchelaar3, Nicole Lo-A-Njoe Kort3, Andre M Sadeghi4, Erwin van Wijk5, Lisbeth Tranebjærg6, Hannie Kremer7, William J Kimberling8, Cor W R J Cremers3, Claes Möller2, Ronald J E Pennings5.   

Abstract

OBJECTIVES: Usher syndrome is an inherited disorder that is characterized by hearing impairment (HI), retinitis pigmentosa, and in some cases vestibular dysfunction. Usher syndrome type IIa is caused by mutations in USH2A. HI in these patients is highly heterogeneous and the present study evaluates the effects of different types of USH2A mutations on the audiometric phenotype. Data from two large centres of expertise on Usher Syndrome in the Netherlands and Sweden were combined in order to create a large combined sample of patients to identify possible genotype-phenotype correlations.
DESIGN: A retrospective study on HI in 110 patients (65 Dutch and 45 Swedish) genetically diagnosed with Usher syndrome type IIa. We used methods especially designed for characterizing and testing differences in audiological phenotype between patient subgroups. These methods included Age Related Typical Audiograms (ARTA) and a method to evaluate the difference in the degree of HI developed throughout life between subgroups.
RESULTS: Cross-sectional linear regression analysis of last-visit audiograms for the best hearing ear demonstrated a gradual decline of hearing over decades. The congenital level of HI was in the range of 16-33 dB at 0.25-0.5 kHz, and in the range of 51-60 dB at 1-8 kHz. The annual threshold deterioration was in the range of 0.4-0.5 dB/year at 0.25-2 kHz and in the range of 0.7-0.8 dB/year at 4-8 kHz. Patients with two truncating mutations, including homozygotes for the common c.2299delG mutation, developed significantly more severe HI throughout life than patients with one truncating mutation combined with one nontruncating mutation, and patients with two nontruncating mutations.
CONCLUSIONS: The results have direct implications for patient counselling in terms of prognosis of hearing and may serve as baseline measures for future (genetic) therapeutic interventions.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27318125     DOI: 10.1016/j.heares.2016.06.008

Source DB:  PubMed          Journal:  Hear Res        ISSN: 0378-5955            Impact factor:   3.208


  19 in total

Review 1.  Antisense Oligonucleotides for the Treatment of Inner Ear Dysfunction.

Authors:  Michelle L Hastings; Timothy A Jones
Journal:  Neurotherapeutics       Date:  2019-04       Impact factor: 7.620

2.  The Era of Precision Medicine: Reshaping Usher Syndrome.

Authors:  Jinsei Jung
Journal:  Clin Exp Otorhinolaryngol       Date:  2020-05-01       Impact factor: 3.372

3.  Tissue-specific genotype-phenotype correlations among USH2A-related disorders in the RUSH2A study.

Authors:  Robert B Hufnagel; Wendi Liang; Jacque L Duncan; Carmen C Brewer; Isabelle Audo; Allison R Ayala; Kari Branham; Janet K Cheetham; Stephen P Daiger; Todd A Durham; Bin Guan; Elise Heon; Carel B Hoyng; Alessandro Iannaccone; Christine N Kay; Michel Michaelides; Mark E Pennesi; Mandeep S Singh; Ehsan Ullah
Journal:  Hum Mutat       Date:  2022-03-21       Impact factor: 4.700

4.  Baseline Visual Field Findings in the RUSH2A Study: Associated Factors and Correlation With Other Measures of Disease Severity.

Authors:  Jacque L Duncan; Wendi Liang; Maureen G Maguire; Isabelle Audo; Allison R Ayala; David G Birch; Joseph Carroll; Janet K Cheetham; Simona Degli Esposti; Todd A Durham; Laura Erker; Sina Farsiu; Frederick L Ferris; Elise Heon; Robert B Hufnagel; Alessandro Iannaccone; Glenn J Jaffe; Christine N Kay; Michel Michaelides; Mark E Pennesi; José-Alain Sahel
Journal:  Am J Ophthalmol       Date:  2020-05-22       Impact factor: 5.488

5.  Clinical and preclinical therapeutic outcome metrics for USH2A-related disease.

Authors:  Maria Toms; Adam M Dubis; Erik de Vrieze; Dhani Tracey-White; Andreas Mitsios; Matthew Hayes; Sanne Broekman; Sarah Baxendale; Nattawan Utoomprurkporn; Doris Bamiou; Maria Bitner-Glindzicz; Andrew R Webster; Erwin Van Wijk; Mariya Moosajee
Journal:  Hum Mol Genet       Date:  2020-07-21       Impact factor: 6.150

6.  Whole exome sequencing identifies novel USH2A mutations and confirms Usher syndrome 2 diagnosis in Chinese retinitis pigmentosa patients.

Authors:  Tsz Kin Ng; Wenyu Tang; Yingjie Cao; Shaowan Chen; Yuqian Zheng; Xiaoqiang Xiao; Haoyu Chen
Journal:  Sci Rep       Date:  2019-04-04       Impact factor: 4.379

7.  Ataluren for the Treatment of Usher Syndrome 2A Caused by Nonsense Mutations.

Authors:  Ananya Samanta; Katarina Stingl; Susanne Kohl; Jessica Ries; Joshua Linnert; Kerstin Nagel-Wolfrum
Journal:  Int J Mol Sci       Date:  2019-12-12       Impact factor: 5.923

8.  Clinical and Haplotypic Variability of Slovenian USH2A Patients Homozygous for the c. 11864G>A Nonsense Mutation.

Authors:  Andrej Zupan; Ana Fakin; Saba Battelino; Martina Jarc-Vidmar; Marko Hawlina; Crystel Bonnet; Christine Petit; Damjan Glavač
Journal:  Genes (Basel)       Date:  2019-12-05       Impact factor: 4.096

Review 9.  Genetics, pathogenesis and therapeutic developments for Usher syndrome type 2.

Authors:  M Stemerdink; B García-Bohórquez; R Schellens; G Garcia-Garcia; E Van Wijk; J M Millan
Journal:  Hum Genet       Date:  2021-07-30       Impact factor: 4.132

10.  Severe or Profound Sensorineural Hearing Loss Caused by Novel USH2A Variants in Korea: Potential Genotype-Phenotype Correlation.

Authors:  Sang-Yeon Lee; Kwangsic Joo; Jayoung Oh; Jin Hee Han; Hye-Rim Park; Seungmin Lee; Doo-Yi Oh; Se Joon Woo; Byung Yoon Choi
Journal:  Clin Exp Otorhinolaryngol       Date:  2019-11-02       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.